Nutex Health (NASDAQ:NUTX) Announces Earnings Results

Nutex Health (NASDAQ:NUTX) issued its earnings results on Thursday. The company reported $5.71 EPS for the quarter, beating the consensus estimate of $5.54 by $0.17, FiscalAI reports. The company had revenue of $217.61 million during the quarter, compared to analysts’ expectations of $214.82 million. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%.

Nutex Health Trading Down 5.6%

Shares of NUTX stock traded down $11.58 on Thursday, hitting $193.64. The stock had a trading volume of 148,231 shares, compared to its average volume of 138,168. The company has a current ratio of 5.00, a quick ratio of 4.96 and a debt-to-equity ratio of 0.59. Nutex Health has a twelve month low of $83.99 and a twelve month high of $226.16. The company has a fifty day moving average price of $203.37 and a two-hundred day moving average price of $151.24. The firm has a market cap of $1.33 billion, a P/E ratio of 8.06 and a beta of 0.66.

Insider Buying and Selling

In other Nutex Health news, Director Scott Saunders sold 203 shares of Nutex Health stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $214.25, for a total transaction of $43,492.75. Following the transaction, the director directly owned 400 shares in the company, valued at approximately $85,700. The trade was a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 44.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NUTX. Wall Street Zen cut Nutex Health from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Lake Street Capital restated a “buy” rating and set a $310.00 target price (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. Weiss Ratings upgraded Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 6th. B. Riley Financial restated a “buy” rating on shares of Nutex Health in a research report on Friday, September 4th. Finally, Zacks Research cut Nutex Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $323.67.

About Nutex Health

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.